introduction Taylor and Jones (1979) showed that incorporation of 5-azacytidine @a-C) into the DNA of the mouse embryonic fibroblast cell line C3HlOTV2 (lOT%) can generate colonies capable of forming muscle, fat, and cartilage. Demethyiation and subsequent expression of specific loci involved in determining each cell type is thought to be involved in the conversion process (Jones and Taylor, 1980) . The frequency of myogenic conversion (as high as 50%) after treatment with aza-C is consistent with the activation of a small number of genes and possibly a single gene (Konieczny and Emerson, 1984) . Genomic DNA transfection experiments indicate that myoblast DNA, but not lOTV!2 DNA, converts lOTV2 cells into stably determined myoblasts at frequencies consistent with transfer of a single genetic locus (Lassar et al., 1988) . Myogenic conversion of 1 OTV2 cells by transfection of myoblast DNA but not lOTV2 DNA supports the hypothesis that a myogenie determination gene that is inactive in lOTV2 ceils becomes structurally modified following treatment with aza-C. The genomic transfection experiments also suggest that lOTV2 ceils do not express Vans-acting factors that can repress the transferred myogenic determination gene. Although it seems likely that the myoD gene is the relevant target of aza-C (lhayer and Weintraub, 1990), it is not known which genes are directly activated by aza-C.
One mechanism controlling activation of myoD during development may be removal or inactivation of negative control. This notion comes from experiments that demonstrated that myoD is subject to trans-negative regulation in primary nonmuscle tissue (Thayer and Weintraub, 1990) . We showed that transfer of human chromosome 11, containing the human myoD locus, from primary dipioid fibrobiasts into lOTV2 ceils results in activation of the human myoD gene and myogenic conversion. in contrast, data obtained from whoieceli hybrids indicates that primary fibrobiasts contain an activity capable of inhibiting myoD activation. Thus, while transfer of human chromosome 11 into 1 OTV'2 cells activates myogenesis, transfer of additional human chromosomes along with chromosome 11 prevents myogenesis. Detailed karyotypic anaiysis of existing hybrids suggest that human chromosomes 4 and 8 are involved in inhibiting activation of myoD (Thayer and Weintraub, 1990) .
We show that chromosome 4, but not 8, inhibits myoD activation in lOTV2 cells. Chromosome fragment-containing hybrids localize the inhibitory locus to the short arm of chromosome 4, in the region containing the homeobox gene MSXl. An examination of early limb development in the mouse reveals a pattern of Msxl expression consistent with a role as 3 negative regulator of myogenesis. We show that Msxl inhibits expression of myoD at the transcriptional level and that this inhibition is likely due to djrect interaction with the myoD enhancer. Furthermore, transfection of chromosome 4 containing lOT% cells with an MSX7 antisense expression vector results in levels of myoD enhancer activity equal to that found in 1 OTV2 ceils. Therefore, we conclude that human MSXl inhibits activation of myoD expression in primary fibroblast x 1 OTV2 cell hybrids.
Results

inhibition of myoD Expression
In lOT% Ceils by Human Fibrobiast Chromosome 4 To dissect the role of chromosomes 4 and 8 on inhibition of myoD expression, we transferred each chromosome, containing neb vector insertions, individually into 1 OT1/2 cells. These microcell fusions generated the lOTV2(4n) and lOT1/2(8n) microcell hybrids, containing human fibroblast chromosomes 4 and 8, respectively. Because microcell fusion often generates hybrids that contain chromosome fragments (Leach et al., 1989) we expected that only a fraction of the hybrids in either series would retain the putative inhibitory locus.
To test the effects of the introduced chromosomes on myoD expression, we initially determined whether the lOTV2(4n) and lOTV2(8n) hybrids could be converted to muscle following treatment with aza-C. Since the endogenous myoD gene is known to be activated in lOTV2 cells treated with aza-C (Davis et al., 1987) and since this activation results in conversion of these cells to muscle, failure of the hybrids to convert to muscle after aza-C treatment would indicate the presence of an inhibitory locus. Cultures of each hybrid clone were exposed to aza-C for 24 hr, plated at clonal density, and grown to -104 cells per colony. Myogenic conversion was assayed by immunostaining with a myosin heavy chain antibody, as described previously (Thayer and Weintraub, 1990) . Four out of five clones from the lOTV2(4n) series hybridscould not be converted to muscle at frequencies similar to control lOTV2 cells (Figure 1 ). The relatively low (1%-50/b) but detectable myogenic conversion of some chromosome 4 hybrids, such as lOTV2(4n)3, 1 OTI/2(4n)-6, 1 OTV2(4n)-8, and 1 OTV2(4n)-10, is due to loss of chromosome 4 sequences in asubpopulation of cells present in each primary hybrid clone (C. D. and M. J. T., unpublished data). In contrast, all of the 1 OTV2(8n) clones convert to the muscle phenotype following treatment with aza-C at frequencies similar to control lOTV2 cells (data not shown). These results suggest that chromosome 4, but not 8, is involved in inhibiting activation of myoD.
We next determined whether expression of myoD mRNA was affected in lOTV2(4n) hybrids that had been treated with aza-C. Parental and hybrid cell cultures were treated with aza-C for 24 hr, plated at clonal density, grown for 14 days, cultured for an additional 4days in differentiation medium, fixed, and immunostained for myosin heavy chain by the alkaline phosphatase method. Colonies were scored as positive if they contained darkly staining multinucleated myotubes.
The values represent the average of two different experiments with >lOO colonies scored for each cell line. 1 OTV2(4n) clones treated with aza-C. Consistent with the myosin heavy chain immunostaining (Figure l) , expression of myoD mRNA is detected in lOTV2 and lOTV2(4n)-1 cells treated with aza-C, but not in lOTV2(4n)-8 cells. In addition, treatment of lOTV2 and lOT1/2(4n)-1 cells with aza-C results in expression of myosin light chain l/3 (MLC) mRNA. Furthermore, consistent with a nonmuscle phenotype and a failure to activate expression of myoD following aza-C treatment, 1 OTV2(4n)-8 cells also fail to express high levels of MLC mRNA. The low level of MLC gene expression seen in these cells is likely due to a minority population of segregant cells, as seen in Figure 1 . 1 OT1/2(4n)-3, 1 OT1/2(4n)-6, and 1 OTV2(4n)-10 also fail to activate myoD and MLC mRNAs following treatment with aza-C (data not shown). These results suggest that a locus present on human chromosome 4 can inhibit activation of mouse myoD in lOTV2 cells treated with aza-C.
Incorporation of aza-C into the DNA of various cell lines induces expressioh of a number of genes, including type C and intracisternal type A particle (IAP) in lOTY2 cells (Hsiao et al., 1986) . In addition, activation of IAP RNA in 1 OTV2 cells treated with aza-C is known to be independent of myoD (Davis et al., 1987) . Therefore, expression of IAP RNA represents a control for activation of gene expression induced by aza-C that does not involve myoD. Figure 2 shows that all three cell lines (lOTV2, lOTV2(4n)-1, and lOTV2(4n)8) activate expression of IAP RNA to similar levels following treatment with aza-C. These results suggest that all three cell lines incorporate aza-C with similar efficiencies and that the inhibitory effect of chromosome 4 on myoD expression is specific. Inhibition of myoD Transcription by Chromosome 4 To define the mechanism of myoD inhibition by chromosome 4, we assayed myoD transcription in the hybrid cells. Enhancer/promoter elements of the human myoD locus that direct correct temporal and spatial expression patterns in transgenic mice have been characterized (Goldhamer et al., 1992) . The human my00 gene contains a basal promoter region located within the first 2.5 kb up- An enhancer core element (closed bar) is located within the 4 kb fragment. The core enhancer (insertion) is 255 bp in length and contains four E boxes (El, E2, E3, and E4) and two putative Msxl-binding sites (Ml and M2) (Goldhamer et al., 1995) . (8) F3/-2.5 CAT is a CAT gene linked to the 2.5 kb promoter and the 4 kb enhancer (Goldhamer et al., 1992) . F3AkCAT and -25W2.5 CAT are virtually the same as F3/-2.5 except that the myoD promoter is replaced by the herpes virus t/r promoter and the 4 kb enhancer by the 259 bp core enhancer element, respectively. (C) iOT%, lOTVz (4n) Figure 3A ). Recently, a 258 bp "core" enhancer element, located within the 4.0 kb enhancer, was identified and retains the ability to recapitulate the temporal and spatial expression pattern in vivo (Goldhamer et al., 1995) . We utilized reporter constructs ( Figure 38 ) consisting of either the 4.0 kb enhancer region (F3) or the 258 bp core enhancer and 2.5 kb promoter region fused with the bacterial chloramphenicol acetyl transferase (CAT) gene.
The constructs were transfected into 1 OTVz , 1 OT%(4n)-1, and lOTV2(4n)-8 cells, and cell extracts were assayed for CAT activity. Figure 3C shows that the CAT activity produced from the 4.0 kb enhancer/promoter construct in iOTV2(4n)-1 was similar to that of lOT% cells, but was approximately 5-fold higher than that of 1 OTV2(4n)-8. Similarly, CAT activities produced by the 258 bp enhancer/ promoter construct were significantly higher in lOTV2 and lOT1/2(4n)-1 than in lOT1/2(4n)-8(P. W. and M. J.T., unpublished data). These results suggest that a locus on human fibroblast chromosome 4 inhibits myoD transcription.
Regional Localization of the Inhibitory Locus Chromosome fragmentation occurs in microcell hybrids, and these fragment-containing hybrids can be used to generate physical maps of the fragmented chromosomes (Leach et al., 1989) . To determine whether the chromosome 4 inhibitory activity could be mapped to a specific chromosomal region, we screened the lOT%(4n) series hybrids for retention of specific DNA sequences, representing genes or unique sequences, known to reside on human chromosome 4. Figure 4 shows a schematic representation of human chromosome 4 with the approximate map positions of the markers tested. Three of the hybrids that retain the inhibitory locus (lOT%(4n)-3, lOTV2(4n)-8, and 1 OT%(4n)-10) retain all markers tested and were uninformative for regional localization. However, lOT%(4n)-1 and lOT%(4n)-8 retain fragments of chromosome 4. lOTV2(4n)-1, which does not retain the inhibitory locus, retains all markers tested except the three most distal short arm markers (D&412, A&Xl, and D4S432). In contrast, lOT%(4n)-8, which does retain the inhibitory locus, retains only four markers, D4S397 and the three most distal short arm markers. Therefore, lOTV2(4n)-1 and lOTV2(4n)-8 retain a nearly completely nonoverlapping set of markers, having only D4S397 in common. Since lOTV2(4n)-8 retains the myoD inhibitory locus and lOTV2(4n)-1 does not, the inhibitory locus must reside in the region of nonoverlap between these two hybrids. This suggests that the myoD inhibitory locus resides on the short arm of chromosome 4 in the region of D4S412, A&Xl, and 043432.
One method for characterizing genes identified by purely genetic approaches is to analyze candidate genes that map to the same chromosomal position. The chromosomal location of the human MSX7 gene in the region of nonoverlap between the hybrids 1 OT1/2(4n)-1 and 1 OT%(4n)-8, as well as the observation that forced expression of Msxl in musclecells results in adecrease in steadystate levels of myoD mRNA (Song et al., 1992) led us to examine MSX7 as a candidate for the myoD inhibitory locus.
Expression of Msxl during Early Limb Development
The pattern of Msxl expression during murine and avian development has been extensively described (Hill et al., 1989; Robert et al., 1989) . A correlation of the distribution of Msxl transcripts in relation to myogenic cells has not been made, although a reciprocal relationship between myogenic differentiation and Msxl expression has been proposed (Wang and Sassoon, 1995) . Mouse forelimbs are first recognizable as outgrowths by 9.25-9.5 days postcoitum (dpc) (-24 somites), and at this stage, cells with myogenic potential can be isolated from limb mesenthyme even though myoD family member gene expression is not detectable (Sassoon et al., 1989; Tajbakhsh and Buckingham, 1994) . To determine whether Msxl is expressed in these early stage limb buds, we performed in situ hybridizations to 9.25 and 10.5 dpc limb buds. Figure 5 shows high level Msxl expression in entire limb mesenthyme at 9.25-10.5 dpc. A similar distribution of Msxl expression has been reported in facial mesenchyme (Mackenzie et al., 1991) , which contains myogenic precursor cells. We conclude that Msxl expression precedes myogenie regulatory gene transcript accumulation during early stages of limb development. Within the limits of resolution of in situ hybridization, Msxl transcripts are present in all mesenchyme of the limb that gives rise to the various tissue types, including skeletal muscle. Thus, the expression pattern of Msxl is consistent with a role as a negative regulator of myogenic differentiation at several embryonic sites, including the limb. Expression of MSXl in Primary Human Fibroblasts and in lOTM(4n) Hybrids One criterion for a candidate inhibitory gene is that it should be expressed in the parental human fibroblast cells, as well as in hybrids that retain the inhibitory locus, but not in lOTI/ cells. We assayed expression of MSXl mRNA in lOTV2 and the lOT1/2(4n) microcell hybrids by Northern blot hybridization. Cytoplasmic RNAs from human skin fibroblast (HSF), lOTV2, lOTV2(4n)-1, and lOT1/2(4n)-8 cells were probed with a labeled fragment of human MSX7 cDNA. The 150 bp probe detects a -2 kb transcript expressed in the human fibroblasts and in lOT1/2(4n)-6, but not in lOTI/ or lOT%(4n)-1 ( Figure 6 ). In addition, we do not detect expression of mouse Msxl mRNA in lOTY2 cells using mouse &xl-specific primers and reverse transcription-poiymerase chain reaction (RT-PCR) (M. J. T., unpublished data). Thus, expression of MSX7 correlates with the presence of the inhibitory locus in primary HSFs and in the hybrids that fail to activate myoD expression.
Forced Expression of Msxl Inhibits myoD Transcription
We had previously generated cell lines that stably express Msxl using F3 myogenic cells (Song et al., 1992) . One cell line from this study (F3 1 -c) expresses very high levels of Msxl and steady-state levels of myoD7 mRNA are not detectable, resulting in lack of differentiation.
CAT constructs containing the human myoD enhancer/promoter elements (see Figure 38 ) transiently transfected into F3 neo (control) and cell lines show that the F3E2.5 CATconstruct produces high CAT activity in control ceils, whereas CAT activities are decreased by P-fold in F3 l-c cells ( Figure 7A) . We further performed cotransfection experiments using a vector to express Msxl (SPHox-7.7) (Songet al., 1992) . In F3 neocells, Msxl reduces CAT activity greater than B-fold ( Figure 7A ), whereas the control construct, SPHox-7R, which contains the Msxl cDNA in the antisense orientation, does not suppress activity. Using a construct containing the myoD enhancer (F3 fragment) fused to the herpes virus thymidine kinase promoter (F3/?k CAT), we see a similar repression of CAT activity in the cotransfection assay with Msxl , and no effect is seen using RSV-CAT as the reporter ( Figure  78 ). Thus, we conclude that the Msxl effects are specific to the myoD enhancer and that the myoD enhancer is a target for Msxi-mediated repression. Msx2, a closely related member of the msh gene family, has a pattern of expression similar to that of Msx7 and contains a nearly identical homeodomain (Monaghan et al., 1991) . To test whether these genes share a common molecular function, we tested the effect of forced expression of MsxP on the myoD regulatory constructs. We observe an inhibitory effect on the human myoD constructs by MsxP similar to those observed with Msxl ( Figure 7C ). To determine whether inhibition is specific to themsh gene family, or whether inhibition is a common feature among all homeoboxcontaining genes, we tested the effects of forced expression of Hoxd4 cDNA on the myoD regulatory C Figure 7 . constructs. As shown in Figure 7C , the Hoxd4 construct has only a small affect on the myoD enhancer activity in the cotransfection assay, suggesting that repression of the myoD enhancer is not a common feature among all homeodomain proteins.
Msxl Binds to the Human myoD Enhancer
We next determined whether repression of the myoD enhancer could be mediated by direct binding of the Msxl protein to the myoD enhancer by using a DNA mobility shift assay. Msxl protein was synthesized in vitro, and SDS-polyacrylamide gel electrophoresis analysis reveals a major translation product with an apparent molecular weight of 32 kDa, corresponding to the size of predicted protein for Msxl (Figure8A). Two additional bandsof lower molecular weight are detected at lower abundance, which likely result from premature termination during the translation or proteolytic degradation. A %P end-labeled probe The major band (arrow) represents the full-length Msxl protein as predicted from the cDNA sequence of Msxl. Two bands of less intensity, likely resulting from premature termination during translation or protaolytic degradation of the full-length protein product, were also detected. Lysate containing no Msxl RNA does not produce radiolabeled protein products. (6) Binding of Msxl to the myoD enhancer was detected by a gel mobility shift assay at different salt concentrations (left lanes: 10 mM Tris (pH 7.5), 50 mM NaCI, 1.5 mM MgCI,, 1 mM DlT, and 5% glycerol; right lanes: the concentration of each component is half those used in the lefl lanes). The KCI concentration of all the lanes is 50 mM. A discrete band (arrow) is seen in the lanes that Msxl proteins were present. A lower band is also observed, which may represent binding by shorter translation products or by more than one Msxl proteins. The probe was an end-labeled PCR product spanning the first 129 base pairs of the myoD core enhancer element.
was prepared from a PC&generated fragment, corresponding to a 129 bp fragment from the 5' end of the 258 bp myoD enhancer. Lysate with no Msxl mRNA was used as a negative control. At least two specific bands are observed in the presence of Msxl protein ( Figure 8B ). The different bands may be due to binding of different size proteins, as is shown in the translation products ( Figure  8A ), or to binding of a number of Msxl proteins to multiple Msxl-binding sites in the probe (see Figure 3A) . These results suggest that repression of the myoD enhancer by Msxl is mediated by binding of Msxl to the myoD enhancer.
Antisense MSX7 Relieves Repression of myoD Transcription To determine whether MSX7 is responsible for inhibition of myoD activation, we tested whether expression of antisense MSXl could relieve repression of myoD transcription in the chromosome 4 hybrids. A genomic MSX7 fragment containing the first exon and -1.0 kb 5' to the transcriptional start site was cloned in the antisense orientation in the expression vector pEMSV (Davis et al., 1987) . This construct was cotransfected with the F3l-2.5 myoD enhancer/promoter CAT construct into 1 OTM , 1 OT%(4n)-1, and lOT1/2(4n)-8 cells. Control constructs included the same MSXl genomic fragment cloned into pEMSV in the sense orientation and the empty parental vector pEMSV. The sense MSXl construct is not expected to have biological activity, since it does not contain the entire second exon, which contains the homeodomain (Hewitt et al., 1991) . Consistent with our previous results, lOTR(4n)-8 contains 5-fold less myoD en hancerlpromoter activity than control cells (Figure 9 ). Significantly, repression of the myoD reporter construct in lOT%(4n)-8 is relieved when cotransfected with the MSX7 antisense construct, but not with the h&Xl sense or pEMSV constructs. Cotransfection of the MSXl expression constructs, either sense or antisense, or the pEMSV vector have no affect on the activity of the myoD reporter gene in 1 OT1/2 or lOT1/2(4n)-1 cells. Furthermore, antisense MSXl has no affect on expression of the control SV40 enhancer/promoter CAT construct in either lOT%, lOT1/2(4n)-1, or lOTI/2(4n)8 cells (data not shown). These results indicate that expression of antisense MSXl can relieve repression of myoD transcription mediated by human chromosome 4. We conclude that h&Xl represents the myoD inhibitory locus present on human chromosome 4, and it functions by inhibiting myoD transcription.
Discussion
We have shown that human fibroblast chromosome 4 is sufficient to inhibit activation of myoD in lOT% cells. This inhibition is mediated through an enhancer located upstream of the myoD gene. The mechanism of inhibition is down-regulation of transcription, since hybrids that contain chromosome 4, as well as cells transfected with an Msxl expression vector, contain significantly less myoD enhancer activity than lOTI/ cells. Furthermore, analysis of chromosome 4 fragment-containing hybrids indicates that the inhibitory locus is localized to the short arm of chromosome 4, which contains human MSXl. Human MSX7 is expressed in the parental primary HSFs, as well as in the lOTI/ hybrids that retain the human MSX7 gene. Cotransfection of an MSX7 antisense expression vector relieves repression and results in levels of myoD enhancer activity equal to that found in lOTI/ cells. Therefore, we conclude that human MSX7 inhibits myoD transcription in primary fibroblast x lOTI/ cell hybrids.
Negative Regulation of myoD Transfer of human chromosome 11 from primary fibroblasts into lOTY2 cells activates human myoD expression (Thayer and Weintraub, 1990) . Subsequent experiments demonstrated that the human myoD enhancer and promoter are functional in lOTI/ cells and that they direct lineage-specific expression in transgenic mice (Goldhamer et al., 1992) . These observations suggest that the human myoD gene is properly regulated in murine cells and that activation of the human myoD gene in lOTY2 cells is not due to improper regulation between species. Although there are several possibilities that could explain why 1 OT1/2 cells normally do not express their own myoD genes, the data are most consistent with the possibility that myoD expression is repressed in cis, probably by methylation (Thayer and Weintraub, 1990) . Consistent with this notion is the observation that the myoD gene is methylated in lOTI/ cells and becomes demethylated following treatment with aza-C (Jones et al., 1990) . The myoD CpG island is highly methylated in immortal cell lines, but is undermethylated in fetal and adult nonmuscle mouse tissues, and becomes methylated when primary mouse fibroblasts are grown in culture (Jones et al., 1990) . Furthermore, transfection of cloned, and therefore unmethylated, mouse myoD genomic fragments converts lOTI/ cells to muscle (Tapscott et al., 1992) . Implicit in this argument is that lOTI/ cells lack the myoD inhibitory activity present in primary fibroblasts. In our model, removal of cis repression by aza-C-induced demethylation would allow low level myoD transcription that is subsequently enhanced by the positive autoregulatory loop (Thayer et al., 1989) . Thus, MSX7 can inhibit this low level of activity and, therefore, can keep myoD silent.
MSX7 Inhibits Expression
of myoD in Fibroblast x 10TM Cell Hybrids Several observations led us to consider MSX7 as a candidate for the myoD inhibitory locus. First, forced expression of murine Msxl in muscle cells results in a dramatic decrease in steady-state levels of myoD mRNA (Song et al., 1992) . Second, the human MSXl gene and the myoD inhibitory locus map to the short arm of chromosome 4. Third, fragment-containing hybrids that retain the MSX7 gene contain the myoD inhibitory activity, while hybrids that have deleted the MSXl gene do not. Fourth, human MSX7 is expressed in primary HSFs and in the chromosome 4 hybrids, while lOTI/ cells do not express endogenous Msxl . Fifth, forced expression of Msxl and the chromosome 4 hybrids repress myoD transcription through the same 258 bp fragment of the myoD enhancer. However, identification of MSXl as the myoD inhibitory locus was established by showing relief of repression of the myoD enhancer by antisense MSXl. Furthermore, Msxl binds to the myoD enhancer and likely functions as a repressor to turn off transcription of myoD. Recently, Msxl has been shown to inhibit transcription of the SV40 enhancer/promoter in the absence of homeodomain DNA-binding sites (Catron et al., 1995) . This repression presumably occurs through protein-protein interactions. Although we observe Msxl binding to the myoD enhancer and repression appears to be mediated through this enhancer, we do not know whether these binding sites are required for repression by Msxl. We note that we do not see an affect of MSX7 on the SV40 enhancer/promoter construct in our chromosome 4 hybrids. This could be explained by a difference in the level of Msxl protein achieved by transient expression versus cell hybridization. Perhaps DNA-binding sites are not required for repression when high levels of protein are produced in the cotransfection assay. The system described here should allow us to determine whether the Msxl-binding sites present in the myoD enhancer are required for repression, or whether Msxl is targeted to the myoD enhancer through protein-protein interactions.
Function of MSXl In Vivo
Msxl is not expressed in all myogenic progenitor cells, such as in the somites (Hill et al., 1989; Robert et al., 1989) . Compelling evidence suggests that myogenic precursors in the somites and those in the limb and other lateral structures represent different lineages and are regulated differently (Ordahl and Le Douarin, 1992) . These two myogenic programs differ in several important ways, including myocyte differentiation (Keynes and Stern, 1988) sensitivity to axial structures (Teillet and Le Douarin, 1983; Rong et al., 1992) and phenotypes resulting from mutationofmyoDfamilymembers (Hastyet al., 1993; Nabeshima et al., 1993) . In addition, Myf5 is expressed in myogenic cells in the dermamyotome prior to myotome formation, while none of the myoD family members are detected until 2 days later in the limbs (Sassoon et al., 1989; Ott et al., 1991; Tajbakhsh and Buckingham, 1994) . The cis regulatory elements have been implicated in the differential expression of the myoD family members. For example, mutation in a conserved E box in the myogenin promoter reduces expression in the limb buds and visceral arches, but has little effect on expression in somites (Cheng et al., 1993) . Taken together, the differential expression of the myoDfamily members may reflect different regulatory factors present in limbs versus somites.
Several experiments implicate Msxl as a negative regulator of muscle development.
Msxl is expressed in the entire limb bud (this study), which contains proliferative and undifferentiated cells including determined myoblasts when limb outgrowth just begins (Hill et al., 1989; Robert et al., 1989) . No transcripts for myoD family members are detected at this stage (Sassoon et al., 1989; Tajbakhsh and Buckingham, 1994) . Although our data indicate that Msxl is expressed in the entire limb bud at early stages and the simplest interpretation is that Msxl is expressed in all cells of the limb bud, without single cell resolution it remains possible that Msxl expression is excluded from myogenic precursor cells. Regardless, at later stages of limb outgrowth, Msxl expression and muscle differentiation are mutually exclusive (Wang et al., 1992) . In addition, dissociation of limb buds from 9.5 day mice results in precocious myoD expression and muscle differentiation accompanied by a rapid decline in Msxl expression (Wang and Sassoon, 1995) . In this study, we see that Msxl represses myoD gene expression at the transcriptional level leading to the conclusion that the myoD gene is a target for a homeobox gene in the muscle lineage and that Msxl represents an important factor that negatively regulates cellular differentiation by repressing myoD. Recent studies suggest that another homeoboxcontaining gene, Pax3, is intimately involved in the process of myoblast migration from the somite to the limb. In situ analysis reveals a 'pathway" of labeled cells that precedes myoD family member transcript accumulation in the limb (Williams and Ordahl, 1994) , and Pax3 mutant mice do not possess limb musculature (Bober et al., 1994) . Thus, homeobox repression of the myogenic differentiation program may be a general mechanism during patterning of early myogenic precursors.
Given our observations that the adipogenic phenotype is also inhibited by chromosome 4 (C. D. and M. J. T., unpublished data), it seems likely that Msxl regulates differentiation of other lineages as well. It will be of interest to determine whether Msxl regulates genes involved in the determination of these other lineages. On6 caveat to this interpretation is the observation that Msxl-deficient mice do not exhibit an obvious limb phenotype, although craniofacial development is severely affected (Satokata and Maas, 1994) . Owing to the close sequence homology and similar expression pattern in the limb, as well as the negative effects on myoD transcription shown here, it seems likely that Msx2 may substitute for Msxl. In addition, MSX2 involvement in limb development is also suggested by the finding of limb anomalies in patients with a mutation in the MSX2 gene causing Boston-type craniosynostosis (Jabs et al., 1993) . It should be possible to test the redundancy hypothesis by constructing mice deficient for both Msxl and Msx2. It should also be possible to test this hypothesis in the hybrid system described here by introducing human chromosome 5, which contains MSX2, into 1OTVz cells and testing for inhibition of myoD activation.
Experimental Procedures CdlS
C3H1OTYz clone 6 was from the American Type Culture Collection. All cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 15% calf serum (Hyclone Laboratories). Cell cultures were exposed to 3 HIM aza-C for 24 hr either one or two times and plated at clone1 density. Myogenic differentiation was induced by growing cells to confluence followed by incubation in DMEM with 2% horse serum (differentiation medium).
Mlcrocell-Medlated Chromosome Transfer
HA(4)-A (mouse A9 cells containing a neo-marked human fibroblast chromosome 4) or HA(S)-A (mouse A9 cells containing a net-marked human fibroblast chromosome 6) cells were micronucleated by adding 0.06 pg of colcemid (Sigma) per milliliter in DMEM plus 10% calf serum for 49 hr. The micronucleate cell populations were enucleated by centrifugation in the presence of 5 Kg of cytochalasin B (Sigma) per milliliter, and the isolated microcells were fused to IOTlh recipients as described (Lug0 et al., 1987) . Microcell hybrid clones were picked after 3-4 weeks of selection in medium containing 500 pg of Geneticin (GIBCO) per milliliter.
Northern
Blot Analysis
Total cytoplasmic RNA was prepared as described (Favaloro et al., 1960) . Either 5 pg of total cytoplasmic RNA or -200 ng poly(A) RNA was used for Northern blot analysis on 1.2% agarose gels containing 6.7% formaldehyde.
RNA was transferred to GeneScreen (DuPont) by capillary transfer in 10x SSC (1 x SSC is 150 mM NaCI, 15 mM Nacitrate).
RNA was cross-linked by exposure to UV light, followed by baking at 60°C for 2-4 hr. Blots were prehybridized for several hours at 42OC in hybridization buffer (50% formamide, 1% bovine serum albumin [fraction V], 1 mM EDTA. 0.5 M sodium phosphate [pH 7.21, 5% sodium dodecyl sulfate [SDS] ). Hybridizations were for 24 hr at 42OC in fresh hybridization buffer containing 1 x 1Q cpm of randomly primed "P-labeled DNA probe. The filters were washed in 2x SSC, 0.1% SDS for 15 min at room temperature, in 0.1 x SSC, 0.1% SDS for 15 min at room temperature, and in two changes of 0.1 x SSC, 0.1% SDS at 55OC for 15 min each. The blots were striped for reuse by boiling for 2 min in double-distilled water. The MSXl probe was generated by PCR of cDNA, the primers were TCAAGCTGCCA-GAAGATGCGCTC and TACGGlTCGTGlTGTGlTTGCGGAG and span the first intron (Hewitt et al., 1991) .
In Sltu Hybrldizatlon
Mouse embryonic tissue was obtained from crosses of BALBlc and C3H strains (Charles River). Matings were confirmed by the presence of a vaginal plug, and the morning following matings was counted as 0.5 dpc. At 9.25 and 10.5 dpc, females were sacrificed and embryos were dissected free of the decidua and somites were counted under a dissection microscope (Wild M3Z) using polarized optics. Tissue was fixed and processed for paraffin microscopy and in situ hybridization using techniques previously described in detail elsewhere (Sassoon and Rosenthal, 1993) . A probe corresponding to Msxl was prepared as described elsewhere (Robert et al., 1969; Wang et al., 1992) . The mice used for this study were also part of a study to confirm that these limbs do not express myoD nor myogenin as detected by in situ hybridization (Sassoon et al., 1989) (Chen and Okayama, 1987) or lipid (Felgner et al., 1987) methods. Approximately 3 x 105 cells were plated 1 day prior to transfection into 80 mm tissue culture plates. The day of transfection, the cells were refed with DMEM plus 15% serum (CaPO,) or DMEM alone (lipid). Several hours later, cells were transfected with 10 pg of DNA per plate comprised of 1 pmol of various CAT reporter plasmids and 2-9 pg of other constructs as shown in the text. The CaPO, precipitate remained on the cells for 24 hr. while the lipid-DNA mixture remained on for 3 hr, after which DMEM plus 15% serum was added. The following day, the cells were refed with DMEM plus 15% serum and harvested 24 hr later.
CAT Assays CAT activity was measured using a phase extraction procedure (Seed and Sheen, 1988) . In brief, 48 hr after transfection. cell extracts were made by freeze-thawing cell pellets in 60 ul of 0.25 M Tris (pH 8.0). Following treatment at 65OC for 15 min to inactivate endogenous acetylases, 30 pl of extract was assayed with 0.2 mCi of [3H]chloramphenicol (Dupont-New England Nuclear) and 250 mM butyryl-CoA (Sigma), in a total volume of 100 pl. The reaction was allowed to proceed from 2-18 hr at 37"C and then stopped by mixing with 200 ~1 of TMPDXylene (2:l) (Sigma), and then 180 pl of the top layer was added to 2 ml of scintillation cocktail and counted. CAT activity was normalized to counts from cells transfected with the control vector pCAT enhancer (Promega).
Results are presented in percentage activity with error bars indicating standard deviation.
In Vitro Translation and Electrophoretlc Moblllty Shift Assay In vitro translation was performed by using rabbit reticulocyte lysate system (Promega) in a50 PI mixture containing 1 .O pgof in vitrosynthesized t&xl RNA, 33 pl of reticulocyte lysate, supplement amino acids (1 mM each), 70 mM KCI, 10 pCi of ["Slmethionine (Dupont-New England Nuclear), 2.4 mM MgC&. and 0.5 U/VI RNasin (Promega) at 30°C for 60 min. The "S-labeled proteins were resolved on a 5% SDS-polyactylamide gel. Prestained molecular weight markers were used to determine the size of labeled proteins. For each gel shift assay, 2.2 PI of lysate containing translation products was incubated with a gel-purified end-labeled probe (105 CPM) in a total volume of 20 pl containing 10 mM Tris (pH 7.5), 50 mM NaCI, 2.5 mM MgCl*, 1 mM DTT, 1.5 ag of poly(dl-dC), and 25-50 mM KCI at room temperature for 15 min. Samples then were resolved on a 5% nondenaturing polyacrylamide gels in 0.4 x TAE (16 mM Tris, 8 mM acetic acid and 0.4 mM EDTA (pH 7.9). Autoradiography was performed with intensifying screen for 14-36 hr at -8OOC. The DNA probe was a PCR product spanning the first 129 bp of the human myoD enhancer core element.
